Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 2/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 16/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 7/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13110978 | 0.81 | PTGS1 (0.53) | PTGS1HDAC1HDAC2HDAC3HDAC8 | |
| SCHEMBL13110901 | 0.80 | PTGS1 (0.48) | PTGS1HDAC1HDAC2HDAC3HDAC8 | |
| SCHEMBL13110932 | 0.78 | HDAC1 (0.49) | HDAC1HDAC2HDAC3HDAC8NCOR2 | |
| SCHEMBL8094966 | 0.78 | HDAC1 (0.47) | HDAC1HDAC2HDAC3HDAC8NCOR2 | |
| SCHEMBL13110903 | 0.74 | HDAC1 (0.46) | HDAC1HDAC2HDAC3HDAC8NCOR2 | |
| SCHEMBL13110748 | 0.74 | HDAC1 (0.54) | PTGS1HDAC1HDAC2HDAC3HDAC8 | |
| SCHEMBL13110941 | 0.74 | HDAC1 (0.48) | HDAC1HDAC2HDAC3HDAC8NCOR2 | |
| SCHEMBL13111073 | 0.72 | TRPV1 (0.41) | PTGS1HDAC1HDAC2HDAC3 | |
| SCHEMBL13111012 | 0.72 | HDAC1 (0.43) | PTGS1HDAC1HDAC2HDAC3HDAC8 | |
| SCHEMBL13110905 | 0.71 | HDAC1 (0.46) | PTGS1HDAC1HDAC2HDAC3HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267779-A1 | Novel Compounds and Methods of Using Them | SYNDAX PHARMACEUTICALS, INC. (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100267779-A1 | Novel Compounds and Methods of Using Them | SYNDAX PHARMACEUTICALS, INC. (US) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267779-A1 | Novel Compounds and Methods of Using Them | HDAC1, HDAC3, HDAC6 | PTGS1 2596/4885HDAC1 1/4885HDAC2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.